AngioDynamics (NASDAQ:ANGO) Issues FY 2025 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of -0.420–0.380 for the period, compared to the consensus EPS estimate of -0.410. The company issued revenue guidance of $282.0 million-$288.0 million, compared to the consensus revenue estimate of $284.4 million. AngioDynamics also updated its FY25 guidance to ($0.42)-($0.38) EPS.

Analyst Ratings Changes

Several research analysts recently weighed in on ANGO shares. HC Wainwright restated a buy rating and issued a $14.00 price objective on shares of AngioDynamics in a research report on Friday. Canaccord Genuity Group lowered their target price on AngioDynamics from $13.00 to $12.00 and set a buy rating for the company in a research note on Friday. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus price target of $12.00.

AngioDynamics Price Performance

Shares of NASDAQ:ANGO opened at $6.10 on Friday. The stock has a market cap of $244.34 million, a price-to-earnings ratio of -1.26 and a beta of 0.65. The company has a 50 day moving average of $7.48 and a 200-day moving average of $6.62. AngioDynamics has a one year low of $5.26 and a one year high of $8.25.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. The firm had revenue of $67.50 million during the quarter, compared to analyst estimates of $67.93 million. AngioDynamics had a negative net margin of 61.55% and a negative return on equity of 4.91%. The business’s quarterly revenue was down 14.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.12) EPS. Equities research analysts anticipate that AngioDynamics will post -0.41 earnings per share for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.